RxDoctor Payments Data

Lynn Lee, MD

Internal Medicine · Valdosta, GANPI 1548298839

Payments from drug & device makers

$2,132in general payments, 2019–2025

Across 117 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$370
  • Novo Nordisk$261
  • Dexcom, Inc.$180
  • Pfizer$167
  • AstraZeneca$158
  • Johnson & Johnson$127
  • plus $871 from 22 others

What the payments were for

  • Speaking & faculty fees$703%
  • Food & beverage$2,06297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,132 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$214,466
Medicare patients
419
Services billed
3,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$119,133
MounjaroTirzepatide81$108,996
EliquisApixaban186$69,965
JardianceEmpagliflozin43$52,748
JanuviaSitagliptin Phosphate25$32,669
FarxigaDapagliflozin Propanediol33$28,076
TrulicityDulaglutide17$13,708
RybelsusSemaglutide11$11,387
RexultiBrexpiprazole22$10,012
TradjentaLinagliptin14$8,952
MyrbetriqMirabegron16$7,944
Potassium Chloride371$5,937
Nateglinide149$5,088
Atorvastatin Calcium472$3,869
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$261$130,519106 claims
Lilly USA, LLCMounjaro, Trulicity$370$122,70498 claims
PfizerEliquis$167$69,965186 claims
Boehringer IngelheimJardiance, Tradjenta$40$61,70057 claims
MerckJanuvia$13$32,66925 claims
AstraZenecaFarxiga, Symbicort$158$30,35244 claims
Astellas Pharma US IncMyrbetriq$26$7,94416 claims
AbbVieSynthroid$83$1,51819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →